spacer
home > ebr > autumn 2017 > a fresh look
PUBLICATIONS
European Biopharmaceutical Review

A Fresh Look

The European Patent Office (EPO) has recently issued guidance to examiners, indicating that the standard disclaimer used in patent applications to confirm that stem cells have been ‘obtained by means that don’t involve the destruction of an embryo’ is no longer required on moral grounds in some circumstances. Specifically, it should not be required if the patent application was filed after 5 June 2003.

While it has not been widely publicised, this subtle shift in position is highly significant and is thought to indicate an acknowledgement by the EPO of the exciting and valuable research work being carried out in this field and its potential to deliver effective stem cell therapies to treat a range of serious medical conditions. Of course, it may also hint at some recognition that practices have moved on and stem cells no longer have to be sourced from embryos.

Legislative Clarification


The change of approach is directly linked to a key date in the evolution of European patent law, when the Court of Justice of the European Union (CJEU) clarified that a parthenote (a cell where division is kick-started by a chemical or electrical method) is not an embryo, thus eliminating the need to source stem cells from an embryo altogether. Until recently, it was only possible to achieve patent protection for inventions involving stem cell research where the patent application was filed after 10 January 2008 with an accompanying disclosure stating that the stem cells had not been obtained from an embryo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Helen Henderson is a senior associate and patent attorney at intellectual property firm, Withers & Rogers. She specialises in advising pharma manufacturers about how to protect novel drug formulations and dosage forms, and she has a particular interest in biotech patents.

Dr Nicholas Jones is a partner and patent attorney at Withers & Rogers. A member of the company’s life sciences and chemistry group, he advises pharma and biopharmaceutical businesses about how to protect their innovations and enforce their intellectual property rights. He also advises UCL Business PLC, the technology transfer arm of the University of London.

spacer
Helen Henderson
spacer
spacer
spacer
Dr Nicholas Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 
Industry Events

12th annual Cold Chain Distribution Conference and Exhibition

13-14 December 2017, Copthorne Tara Hotel, London, UK

Responding to the evolution within the industry, SMi is proud to announce the return of its leading 12th annual Cold Chain Distribution event. Returning to London in December, this year's event will remain at the forefront of innovation
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement